#152: Even nonobstructive CAD at CT predicts risk in symptomatic patients: CONFIRM; FDA approves EPA-only omega-3 PUFA capsule; Aggressive heart-rate control reduces radiation from CCTA; rivaroxaban gets NICE thumbs-up for DVT; BMJ analysis: TAVI is vastl

Summary: For the week ending August 3, 2012 we discuss the following top cardiology news from heartwire: • CONFIRM: Even nonobstructive CAD at CT predicts risk in symptomatic patients • FDA approves EPA-only omega-3 PUFA capsule for high TG • Aggressive heart-rate control reduces radiation from CCTA • Rivaroxaban gets NICE thumbs-up for DVT • BMJ analysis: TAVI is vastly overused And also, in brief: • Exercise training improves depressive symptoms in heart failure: HF-ACTION • Endoscopic bypass vein-graft harvesting no worse than open method • Screening ECG unnecessary for asymptomatic adults: USPSTF Join us for a comprehensive review of this week's most important cardiology news.